Clinical trials: Aspergillosis Invasive
Mycoses
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A: which are refractory or resistant to…
- Trial name
- NCT00034658
- Testing
- Posaconazole
- Volunteers
- 336 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis, Invasive Pulmonary
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time…
- Trial name
- AzorMan (NCT03121235)
- Testing
- PCR based detection of azole resistance in A. fumigatus
- Where
- 8 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center
Adverse Drug Reactions
The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole
Voriconazole is a drug used to treat invasive fungal infections. The amount of voriconazole in a person's blood helps to determine how effectively it treats an infection, and how safe it is.
- Trial name
- NCT04547335
- Testing
- Voriconazole
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Dokuz Eylul University
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Infections
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
- Trial name
- FORMULA-OLS (NCT03583164)
- Testing
- Olorofim
- Where
- 82 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- F2G Biotech GmbH
Invasive Pulmonary Aspergillosis
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
- Trial name
- SCYNERGIA (NCT03672292)
- Testing
- SCY-078, Voriconazole
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Scynexis, Inc.
Aspergillosis
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA).
- Trial name
- NCT00037206
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
In previous retrospective study (SEIFEM 2016 study) the investigators evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of mold active primary antifungal prophylaxis (PAP) in a "real life"…
- Trial name
- NCT06382922
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Rome Tor Vergata
Liver Transplantation, Fungal Infection
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
This is a non-comparative, open, multisite prospective estimation study to evaluate the efficacy and safety of caspofungin in the prophylactic treatment of adults who have received an orthotopic liver transplant and are at high…
- Trial name
- NCT00333645
- Testing
- Caspofungin
- Where
- 13 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Grupo de Estudio de Infecciones en Transplantados
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
RATIONALE: Antifungals such as voriconazole may be effective in controlling fungal infections. Combining voriconazole with interferon gamma may be more effective than voriconazole alone in treating fungal infections.
- Trial name
- NCT00059878
- Testing
- recombinant interferon gamma, voriconazole
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Aspergillosis; Pulmonary, Invasive (Etiology)
Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza.
- Trial name
- POSA-FLU (NCT03378479)
- Testing
- SOC +Posaconazole 18 MG/ML (milligram/milliliter), standard of care (SOC)
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 88 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adverse Drug Reactions
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy
Voriconazole is a drug used to treat invasive fungal infections. The amount of voriconazole in a person's blood helps to determine how effectively it treats an infection, and how safe it is.
- Trial name
- NCT04743544
- Testing
- Voriconazole
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Dokuz Eylul University
Candidiasis, Cryptococcosis
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections
- Conditions
- Candidiasis, Cryptococcosis, Aspergillosis
- Trial name
- NCT00647907
- Testing
- Voriconazole
- Where
- 4 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Olorofim Aspergillus Infection Study
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus…
- Trial name
- OASIS (NCT05101187)
- Testing
- Olorofim, AmBisome®
- Where
- 143 sites in United States, Australia and 19 more
- Volunteers
- 225 people
- Sponsor
- F2G Ltd
Pulmonary Invasive Aspergillosis
Application of an Electronic Nose in the Early Detection of ASpergillosis
The purpose of this study is to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls.
- Trial name
- AENEAS (NCT01395446)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Invasive Aspergillosis
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).
- Trial name
- NCT04218851
- Testing
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Where
- 29 sites in United States, Belgium and 8 more
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study. Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group consisting of 8 subjects.
- Trial name
- ORALMAD (NCT02737371)
- Testing
- F901318 Dose level A oral, F901318 Dose level B oral, F901318 Dose level C oral
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Influenza With Pneumonia, Pulmonary Aspergillosis
Prospective Observational Trial of IAPA
A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU…
- Trial name
- IAPAFLU (NCT04530799)
- Testing
- Identification of biomarkers for IAPA via patient sampling
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 241 people
- Sponsor
- Radboud University Medical Center